Search Press releases Keywords From To 5 Dec 2025 UCB Upgrades 2025 Financial Guidance Based on Strong Performance Read More 4 Dec 2025 UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting Read More 6 Nov 2025 UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation Read More 3 Nov 2025 U.S. FDA approves KYGEVVI[™] (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) Read More 31 Oct 2025 BIMZELX[®] (bimekizumab-bkzx) data in hidradenitis suppurativa showed improvements in pain and resolution of draining tunnels sustained to three years Read More 29 Oct 2025 UCB to unveil new data for RYSTIGGO[®▼]and ZILBRYSQ[®▼] for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session Read More Pagination First page Previous page Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Page 5 of 63 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
